Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 3/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6039806 | 0.84 | EPHX1 (0.32) | EPHX1ALDH1A1HPGDKMT2A | |
| SCHEMBL5098580 | 0.78 | ALDH1A1 (0.32) | MCL1ALDH1A1 | |
| SCHEMBL2930546 | 0.77 | HPGD (0.50) | EPHX1ALDH1A1HPGDRAB9ANPC1 | |
| SCHEMBL3549456 | 0.75 | EPHX2 (0.38) | — | |
| SCHEMBL4803959 | 0.75 | EPHX1 (0.41) | EPHX1KDM4EALDH1A1RAB9ACYP3A4 | |
| SCHEMBL2916000 | 0.74 | SLC6A12 (0.36) | ALDH1A1 | |
| SCHEMBL1414189 | 0.74 | SLC6A12 (0.36) | ALDH1A1 | |
| SCHEMBL10170261 | 0.74 | HPGD (0.53) | EPHX1HPGDRAB9ANPC1KMT2A | |
| SCHEMBL693202 | 0.72 | — | — | |
| SCHEMBL7449462 | 0.72 | KMT2A (0.40) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1084710-B1 | ADENOSINE A1 ANTAGONISTS FOR MALE STERILITY | ASTELLAS PHARMA INC (JP) | 2006-10-18 | — | — | EP | disclosed |
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-08-05 | — | — | US | disclosed |
| US-6521656-B1 | Contacting sperm with a pyrazolo(1,5-a)pyridine acrosomal reaction induction promoter then joining with ovum | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| EP-0823254-B1 | NOVEL USE OF PYRAZOLOPYRIDINE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-07-17 | — | — | EP | disclosed |
| EP-1177797-A9 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| EP-1177797-A1 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-06 | — | — | EP | disclosed |
| US-6303624-B1 | PREVENTION AND/OR TREATMENT OF HYPERPHOSPHATEMIA OR SECONDARY HYPERPARATHYROIDISM, INCLUSIVE OF ACCESSORY DISORDERS BY ADMINISTERING A PHARMACEUTICAL COMPOSITION WHICH COMPRISES AN ADENOSINE ANTAGONIST COMPOUND OR ITS SALT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-16 | — | — | US | disclosed |
| US-6232324-B1 | AS HYPERTENSIVE AGENTS FOR DIALYSIS INDUCED HYPOTENSION; ADMINISTERING COMPOUNDS SUCH AS 1-(3-(2-PHENYLPYRAZOLO(1,5-A) PYRIDIN-3-YL)ACRYLOYL)-2-(CARBOXY METHYL)PIPERIDINE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-15 | — | — | US | disclosed |
| US-6214843-B1 | TREATING AND/OR PREVENTING GASTROINTESTINAL DYSFUNCTION WITH A PYRAZOLOPYRIDINE COMPOUND WHICH COMPRISES AN ADENOSINE ANTAGONIST COMPOUND OR ITS SALT | FUJITSAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-04-10 | — | — | US | disclosed |
| EP-1084710-A1 | REMEDIES FOR MALE STERILITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-21 | — | — | EP | disclosed |
| EP-0972525-A1 | PREVENTIVES AND REMEDIES FOR HYPERPHOSPHATEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-19 | — | — | EP | disclosed |
| EP-0900796-A1 | PREVENTIVES AND REMEDIES FOR ISCHEMIC INTESTINAL LESION AND ILEUS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-03-10 | — | — | EP | disclosed |
| EP-0823254-A1 | NOVEL USE OF PYRAZOLOPYRIDINE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | ADORA2A, ADORA1, ADORA2B | EPHX1 1675/4885MCL1 4734/4885FAAH 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.